secwatch.observer — SEC 8-K summary
======================================

Issuer:     RAPID MICRO BIOSYSTEMS, INC. (RPID)
CIK:        0001380106
Form:       8-K
Filed at:   2023-01-11T23:59:59+00:00
Accession:  0001380106-23-000004
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rapid Micro Biosystems prelim FY2022 revenue $17.0-17.2M; Q4 $4.2-4.4M; cash $140M
--------------------------------------------------------------------------------

- FY2022 commercial revenue expected $17.0-17.2M; Q4 revenue $4.2-4.4M, in line with expectations.
- Placed 9 new Growth Direct systems and completed validation of 19 systems in FY2022.
- Ended 2022 with ~$140M cash and investments, providing runway at least into 2026.
- Added new global Top 20 pharma customer in U.S. and large pharma customer in Japan.
- Launched RMBNucleus Mold Alarm software; to present at J.P. Morgan Healthcare Conference Jan 12.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1380106/000138010623000004/0001380106-23-000004-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1380106/000138010623000004/rpid-20230111.htm
  HTML page:      https://secwatch.observer/filing/0001380106-23-000004

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer